Xinyue Biotechnology Completes Tens of Millions RMB Pre-A+ Financing to Accelerate DEL 3.0 Platform and Innovative Drug Development

Recently,Shenzhen NewDEL Biotech Co., Ltd. (hereinafter referred to as "NewDEL Biotech") announced the completion of a Pre-A+ round of financing worth tens of millions of yuan, with this round of investment jointly made by Shenzhen HTI Group Co., Ltd., Hecheng Capital and other institutions.Out of confidence in the company's development prospects, the core technology team of NewDEL Biotech continued to increase their shares in the company at the same price as the previous two rounds of financing. This round of financing will be used to advance the development of the DEL3.0 technology platform (integration of DNA Encoded Library technology with AI), clinical trials of ongoing new drug projects, and preclinical research.

NewDEL Biotech is the first biopharmaceutical company incubated by the Guangdong Province Small Molecule New Drug Innovation Center. It possesses a globally leading DEL live-cell screening technology and an AI-integrated technology platform. Thanks to the trust and support from all parties and the concerted efforts of the entrepreneurial team, NewDEL Biotech has achieved remarkable progress in just over two years since its establishment, including advancements in technology platform development, team building, pipeline layout, and external collaborations.Built a full-industry-chain team for new drug development from the DEL Technology Center to the Business Marketing Department, constructed the DEL 3.0 technology platform and dozens of R&D pipelines. The first Class I new drug project, ND-003, has been approved by the FDA for clinical trials, and business cooperation has been reached with dozens of pharmaceutical companies.

Meanwhile, NewDEL Biotech has appointed Dr. Xiaoyu Li, Professor Ke Ding, Dr. Nick Terrett, and hospital experts from academia, industry, and clinical fields to form a top-tier Scientific Advisory Committee. This committee will collaborate to empower the entire process of NewDEL Biotech's new drug development, creating a closed-loop system where translational medicine and clinical feedback flow bidirectionally between basic research and clinical studies, enhancing each other.

"Following the completion of a multi-million yuan Pre-A round of financing a year ago, we are very pleased to receive additional investment from well-known investment institutions. We sincerely thank all new and existing investors for their high recognition and strong support."Mr. He Xun, founder and chairman of NewDEL Biotech, said"This financing will further accelerate the advancement of the company's technology platform and project pipeline layout. The company expects to obtain three additional IND clinical permits for innovative drugs in both China and the U.S. by the end of this year. As pharmaceutical professionals, we always focus on unmet clinical value and aim to produce affordable medicines for the public as our ultimate goal. To help global patients gain access to more effective and safer original innovative drugs as soon as possible, we are sparing no effort, working day and night to achieve breakthroughs in cutting-edge technologies and advance clinical transformation."

The project leader of Shenzhen HTI Group Co., Ltd. stated:As a Shenzhen-based company, the biopharmaceutical industry is one of the key areas supported by Shenzhen's "20+8" industrial policy. NewDEL Biotech's DEL3.0 technology platform stands out with its uniqueness and differentiation. This new technological tool is expected to be a pivotal factor in transforming the current state of new drug development. This investment not only reflects confidence in the future growth potential of DEL3.0 new drug discovery technology but also signifies high recognition of the company’s team. We look forward to the company’s technology platform yielding more achievements and fruitful results, benefiting the public and society at large.

Honest Capital ManagementFull of confidence in this investment: "NewDEL Biotech has a solid and stable team, efficient execution capabilities, and unique technological advantages, which ensure the timely completion of various milestones. In the future, it will undoubtedly grow into a high-tech biotechnology company with significant industry technological advantages and distinctive characteristics. The company currently has a complete full-industry chain team, its platform technology has been very well validated, and it has laid out dozens of new drug pipelines at different stages of development. The ND-003 project has received FDA clinical approval, marking the company's leap from the preclinical stage to the clinical stage within just two years. Therefore, we have high expectations for the company's future success."

Shenzhen HTI Group Co., Ltd. was established in 1994 as a professional financial services institution set up by the Shenzhen Municipal Committee and Municipal Government to address the financing difficulties of small and medium-sized technology enterprises. It holds the highest AAA credit rating in the capital market. Currently, the group's paid-in capital exceeds 13.8 billion yuan, with net assets of 24.3 billion yuan and total assets of 44.7 billion yuan. Its businesses cover bank loan guarantees, engineering guarantees, bond credit enhancement, venture capital, fund management, micro-loans, pawnbroking, and commercial factoring, providing enterprises with comprehensive investment and financing services from the start-up stage to the mature stage.

For more than two decades, Shenzhen HTI Group has adhered to the mission of serving small, medium and micro technology-based enterprises, growing together with numerous small and medium-sized technology companies. Enterprises it has supported, such as Huawei, BYD, Skyworth, Han's Laser, and Hytera, have become well-known companies domestically and even internationally. The group has successively assisted over 370 companies in going public through listings on domestic or overseas stock exchanges. Staying on the main course of "financial services for the real economy," the company uncovers the value potential of technology enterprises, focuses on customers, empowers innovators, and strives unremittingly for the construction of Shenzhen as a pilot demonstration area of socialism and for building China into a global leader in science and technology.

Zhuhai Hecheng Zhiyi Capital Management Co., Ltd. (Hocheng Capital) was founded in 2015 as a professional investment management firm dedicated to long-term value investing. As a venture capital institution, the company upholds the core values of "Harmony and Integrity" and is committed to investing in and incubating innovative enterprises with "core technology," while nurturing and empowering leading "chain leader" enterprises. It has successfully invested in multiple high-tech companies specializing in information technology, advanced manufacturing, new materials, and biopharmaceuticals.